about
Melanoma incidence increases in the elderly of Catalonia but not in the younger population: effect of prevention or consequence of immigration?A new era in the management of psoriasis? The biologics: facts and controversies.Angiogenesis in Dermatology - Insights of Molecular Mechanisms and Latest Developments.Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.Generalized Leishmanides in an Immunodeprived Man.Mucous membrane ulcers in an immunocompromised patient. Cutaneous cytomegalovirus infection.Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.CCL4L polymorphisms and serum levels are associated with psoriasis severity.Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study.Author's reply to: Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis-Reply.Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.Disseminated Strongyloides stercoralis infection with a cutaneous presentation in an immunosuppressed patient.Lymph Node Dissection in Patients With Melanoma and Sentinel Lymph Node Metastasis: An Updated, Evidence-Based Decision Algorithm.Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% for Actinic Keratosis Treatment In Spain.Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain.Cutaneous toxicities of new treatments for melanoma.CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis SeverityEarly outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort studyAllergic contact dermatitis to 2(thiocyano-methylthio) benzothiazole present in a packaging wood[Skin lesions in the diabetic foot][Keloid development on skin lesions after the application of a cream purchased over the internet][Tinea capitis in elderly women: a report of 4 cases]Angiomatous Proliferation Hiding a Metastasis of Melanoma[Bridging the Digital Divide]Massive cutaneous nodules in a 92-year-old manLeadership in the Treatment of Skin CancerA dermoscopic pitfall in a long-standing tumorIncreasing incidence of lentigo maligna and lentigo maligna melanoma in CataloniaFactors associated with sentinel lymph node status and prognostic role of completion lymph node dissection for thick melanomaSleep-Disordered Breathing Is Independently Associated With Increased Aggressiveness of Cutaneous Melanoma: A Multicenter Observational Study in 443 PatientsEnhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with PembrolizumabEpidemiology of dermatophytic infections between 2008 and 2017 in Barcelona, SpainCutaneous Melanoma in the Elderly: Review of a Growing ProblemDermatoskopischer Fallstrick bei einem langjährig bestehenden TumorSurvival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study
P50
Q36578597-4FBB517F-955E-4036-AED9-91BD43A59521Q37677141-ACF723F1-D8DD-4DCF-97DD-3D15CD8AB1BDQ38761391-C99CCA79-2C42-401F-B262-7A30E07E7630Q39570689-75FA0ADC-9F2E-482C-9E2D-91140F1BCD35Q40353583-D14FDE19-77BF-49E2-978F-95EAFACAF943Q43552248-638BE228-3C21-4309-A5D6-E04B005AD05CQ45728702-F235C221-4A32-4C6B-AEF9-864E60B1A871Q46554715-0F7D7FF4-3644-4C97-B827-ACC8BE5D5C7DQ48273215-D8173794-E906-4928-8C25-88D9378F8530Q48274531-303A342C-0A5E-4072-B1D4-BDE1C7EC9DE2Q49722393-BD06C53E-B8A1-406C-BA22-9CFA3A18C44AQ50533035-268D3288-0CF4-470C-B803-B47C26A62BB3Q50857264-959EB90E-BF22-466A-8AB0-8A8A0E212238Q52697562-6CBFA73A-8A67-4465-91FF-59B32262E739Q53823214-DDA3CDF6-09F9-4E6E-BF0B-783A64B8CDBDQ53827416-CE9B5F73-38C4-4461-98C9-A652DE98FBA0Q53843570-E104B442-1E0C-4FED-BA45-4C4EA4AFBBB4Q53843572-6E38D098-A305-4043-891F-7523F2831E62Q60566835-2D047B12-6BD4-4B38-B2F6-614DE635D10EQ61905788-EF646B9C-970C-404C-A874-EA60325BA67DQ64089304-CA04CCC1-8F70-4957-9478-B5ED25F85E28Q80603899-4ADE3C5B-037B-4DD1-9E78-F9903D5996CCQ82999610-2A011F61-7C42-4351-93BD-F8C44D8DD301Q83399493-05F7BABD-E21D-4970-807C-B21E94111C43Q84140841-AB5E26FA-6EAD-416C-9519-78EF1DBDC04EQ86454850-1B0967EE-AB39-48B1-9D79-3E773455B3C6Q87239430-912A5C6B-509F-4B42-86DE-88A291CA2056Q88049193-A690C31A-FCAF-420D-9214-E1CC01EB34A8Q90047234-BA00D1A7-ABA6-4D3A-AE2B-71F059F658B5Q90230568-E173305C-E8A5-4364-96E5-3747F26B17EEQ90481361-7AB48A88-3D80-4700-BCFA-8CE82C796471Q90596254-9930DD5A-028A-436B-AC30-EC34E97E7D7CQ90613032-19695FB9-8B6D-4B58-B03B-1C46D6CB58C5Q91726914-6549409D-36DD-4FDB-A10C-32700B50449AQ91926535-10955A4B-0B5C-4219-96A8-5253A75E388BQ92121875-4980359F-DF0E-418F-B4C8-15183E10F529Q92211244-3B7ABBE1-656B-48B7-9306-73E3676FA3EDQ92869117-00A1086B-3654-4880-BDE1-FAE64987265B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Aram Boada
@ast
Aram Boada
@en
Aram Boada
@es
Aram Boada
@nl
Aram Boada
@sl
type
label
Aram Boada
@ast
Aram Boada
@en
Aram Boada
@es
Aram Boada
@nl
Aram Boada
@sl
prefLabel
Aram Boada
@ast
Aram Boada
@en
Aram Boada
@es
Aram Boada
@nl
Aram Boada
@sl
P106
P21
P31
P496
0000-0001-9809-5308